Physician profile
Celso R Chavez
NPI 1386795565
$1,520.54
in general payments reported to CMS, 2019-2025
26 companies · $37.50 in 2025
The $37.50 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $599 · 2020: $134 · 2021: $26.00 · 2022: $579 · 2023: $145 · 2025: $37.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $182.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $228.08 | 2019-2022 | |
| Abbvie INC. | $227.67 | 2022-2023 | Qulipta, Vraylar |
| Teva Pharmaceuticals USA, INC. | $117.84 | 2019 | |
| Amgen INC. | $102.07 | 2019-2022 | |
| Pfizer INC. | $96.04 | 2020-2023 | |
| Sanofi-Aventis U.S. LLC | $92.23 | 2019-2022 | |
| Astellas Pharma US INC | $87.45 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.80 | 2022 | |
| Lilly USA, LLC | $58.72 | 2022-2023 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $57.62 | 2019-2022 | |
| Mylan Specialty L.P. | $50.00 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $38.16 | 2019-2023 | Spravato |
| Abbott Laboratories | $37.50 | 2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $34.65 | 2019 | |
| Electromed, INC. | $31.87 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $29.07 | 2019 | |
| Exact Sciences Corporation | $23.77 | 2023 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $21.87 | 2020 | |
| Novartis Pharmaceuticals Corporation | $21.20 | 2022 | |
| Amag Pharmaceuticals, INC. | $18.74 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $17.20 | 2023 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $17.10 | 2022 | |
| Allergan, INC. | $16.89 | 2020 | |
| Gilead Sciences, INC. | $11.86 | 2019 | |
| Phadia US INC. | $11.24 | 2020 | |
| Therapeuticsmd, INC. | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celso Chavez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.